Invivomab polyclonal mouse igg

Cells were either pretreated with circulating sEVs or cell‐line‐derived sEVs before performing functional assays. Cells were seeded at a density of 3 × 10⁴ in 6‐well culture plates and treated with 2.5 µg mL⁻¹ of sEVs for 72 h. To neutralize vWF, 1 µg mL⁻¹ anti‐vWF neutralizing antibody (#SAB1408640, Sigma–Aldrich) was added to cell culture. To neutralize VEGF‐A and FGF2, 2 µg mL⁻¹ anti‐VEGF‐A (#MAB293, R&D Systems) and anti‐FGF2 (#AF‐233, R&D systems) antibodies were added to cell culture. For control set‐up of neutralizing experiment, cells were treated with InVivoMAb polyclonal mouse IgG (#BE0093, BioXCell) or polyclonal rabbit IgG (BE0095, #BioXCell) using the same concentration as the tested experimental group.

C57BL/6J or Rag1^−/− mice were given an intraperitoneal (i.p.) injection with 1 mg per mouse of either anti‐NK1.1 (PK136) mAb or InVivo MAb Polyclonal Mouse IgG (both from BioXCell, West Lebanon, New Hampshire, USA) on alternate days, starting from the day before infection.
Ncr1‐iCre x iDTR mice were given 8 ng g⁻¹ (based on body weight) of DT from Corynebacterium diphtheria (Sigma‐Aldrich^®) per mouse 2 days and 1 day prior to infection and every 2 days after infection. Control mice were given an equal volume of sodium chloride (0.9% [w/v]) for irrigation (Baxter International, Deerfield, IL, USA). Depletion efficacy in both models was determined by flow cytometry analysis using an anti‐mouse mAb towards NKp46 (CD335; 29A1.4) (BioLegend).